The most consequential detail in an Obagi Clear comparison is the small suffix. Clear Rx and Clear Fx are not two interchangeable spellings for one product. A reader researching melasma needs the prescription status and actual ingredient identity to remain obvious from the directory through to the purchase discussion.
Tone Notes checked Obagi’s official Rx and Fx pages and US store policy on October 14, 2026. We did not obtain a prescription, buy either product or assess treatment results. The review compares the published identities and terms without assuming that one formula’s evidence, price or return policy belongs to the other.
- Clear Rx
- Hydroquinone 4% / 40 mg per gram; prescription
- Clear Fx
- Arbutin cosmetic; no hydroquinone declared
- Fx price observed
- $125; Rx quote unverified
- Policy boundary
- US store terms do not automatically cover a dispensing pharmacy
- Comparison limit
- No independently appraised current head-to-head melasma trial
Clear Rx declares four-percent hydroquinone
The official prescription page identifies hydroquinone at 4%, equivalent to 40 mg per gram. That is the drug ingredient declaration for Clear Rx. Its prescription pathway brings eligibility, clinical assessment and the actual dispensing arrangement into the comparison; a public product page does not complete those steps. [1]
The specific pharmacy quote, insurance contribution and inventory were not established here. Our hydroquinone guide discusses why supervision is part of the product’s context. This review provides no dosing schedule and makes no individual determination that a hydroquinone preparation is appropriate.
Clear Fx uses a different ingredient identity
Clear Fx is the cosmetic counterpart reviewed through the separate US store listing. That page identifies arbutin and does not declare hydroquinone in the formula. The shared Nu-Derm family and Clear naming do not turn it into the four-percent prescription preparation or establish an equivalent response. [2]
The Fx page displayed $125. That retail amount must not be used as a price quote for Clear Rx, whose actual dispensing cost remains unverified. A comparison table is only helpful when the exact name, active or cosmetic ingredient identity and route remain attached to their respective figures.
The melasma question still requires clinical context
AAD describes prescription hydroquinone among possible melasma treatments while emphasizing diagnosis and an individualized plan. That guidance does not establish that every discoloration is melasma, endorse a specific Obagi purchase or show that Clear Fx produces the same effect as an Rx preparation. [4]
Our diagnosis discussion is a useful companion to the product names. The evidence boundary is especially important here because a shared brand can make different routes appear equivalent. This article does not infer a particular regulatory indication for a specific product from a general ingredient discussion.
The finished-product comparison remains incomplete
We did not independently appraise a full head-to-head study of these two current formulations in a defined melasma population. Their ingredient differences are documented facts, but those facts do not quantify the difference in visible results, tolerability or time to change for a particular reader.
Manufacturer descriptions and product-family familiarity are not replacements for that study. The retail-versus-care guide keeps cosmetic support and prescribed treatment in their proper contexts. It also avoids presenting a store’s product sequence as a personal medical plan or assuming additional products are necessary.
The US store policy should not be assigned to a pharmacy
Obagi’s US direct-store refund terms describe a thirty-day period from delivery, with original shipping excluded and samples treated as final sale. The store also displays a free-shipping threshold of $165, so the captured $125 Fx price alone does not satisfy that amount. Actual checkout charges were not tested. [2] [3]
A prescription dispensed through a separate pharmacy may be governed by different terms. This review does not promise that the direct-store policy covers Clear Rx. The responsible seller, dispensing route and applicable cancellation or return rules should be identified before a reader relies on any summary.
Bring the complete name to the dispensing conversation
A note that says only Obagi Clear is incomplete for this comparison. Keeping Rx or Fx attached reduces the chance that a retail price, ingredient claim or return rule will be applied to the wrong preparation. The packaging and seller should agree with the identity being discussed.
For an Rx route, the prescriber and dispensing pharmacy can address the actual preparation and order. The public directory does not replace those records. For Fx, the cosmetic listing still requires its own full formula and selected purchase terms rather than borrowed prescription assumptions.
Keep the suffix visible throughout the decision
A useful shortlist can include both products while making their differences explicit: Clear Rx has declared hydroquinone and a prescription route, while Clear Fx is a separately priced arbutin cosmetic. That pairing is an identity comparison, not a recommendation to switch products or assume matching outcomes.
AAD’s self-care material also places sun protection and irritation avoidance within the melasma discussion. The sun-protection article develops that context. CoreAge Rx’s paid feature is independent of this evidence assessment; neither commercial order nor a familiar brand name supplies the missing comparative clinical result. [5]
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Dark Spot Lightener & Corrector Cream | Obagi Nu-Derm® RxOfficial product or purchase record; claims and transaction performance not independently tested · Checked October 14, 2026
- Skin Brightening Cream | Obagi Clear FxOfficial product or purchase record; claims and transaction performance not independently tested · Checked October 14, 2026
- Refund policy – ObagiOfficial product or purchase record; claims and transaction performance not independently tested · Checked October 14, 2026
- AAD: melasma diagnosis and treatmentAAD guidance rechecked October 10, 2026. · Checked October 14, 2026
- AAD: melasma self-careAAD guidance rechecked October 10, 2026. · Checked October 14, 2026